397 related articles for article (PubMed ID: 18025877)
1. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
[TBL] [Abstract][Full Text] [Related]
2. Reduced lopinavir exposure during pregnancy.
Stek AM; Mirochnick M; Capparelli E; Best BM; Hu C; Burchett SK; Elgie C; Holland DT; Smith E; Tuomala R; Cotter A; Read JS
AIDS; 2006 Oct; 20(15):1931-9. PubMed ID: 16988514
[TBL] [Abstract][Full Text] [Related]
3. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
4. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
5. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
6. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
7. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.
Martinez-Rebollar M; Lonca M; Perez I; Soy D; Brunet M; Martin R; Coll O; Hernandez S; Laguno M; Milinkovic A; Larrousse M; Calvo M; Blanco JL; Martínez E; Gatell JM; Mallolas J
Ther Drug Monit; 2011 Dec; 33(6):772-7. PubMed ID: 22105596
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
10. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
Mandelbrot L; Mazy F; Floch-Tudal C; Meier F; Azria E; Crenn-Hebert C; Treluyer JM; Herinomenzanahary E; Ferreira C; Peytavin G
Eur J Obstet Gynecol Reprod Biol; 2011 Jul; 157(1):18-21. PubMed ID: 21492993
[TBL] [Abstract][Full Text] [Related]
11. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Moltó J; Deig E; Valle M; Maria Llibre J; Miranda C; Cedeño S; Valero S; Negredo E; Clotet B
Ther Drug Monit; 2010 Feb; 32(1):93-6. PubMed ID: 20040897
[TBL] [Abstract][Full Text] [Related]
12. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
[TBL] [Abstract][Full Text] [Related]
13. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
von Hentig N; Nisius G; Lennemann T; Khaykin P; Stephan C; Babacan E; Staszewski S; Kurowski M; Harder S; Haberl A
Antivir Ther; 2008; 13(8):1039-46. PubMed ID: 19195329
[TBL] [Abstract][Full Text] [Related]
15. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S
J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
[TBL] [Abstract][Full Text] [Related]
16. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.
Gingelmaier A; Kurowski M; Kästner R; Eberle J; Mylonas I; Belohradsky BH; Friese K; Grubert TA
AIDS; 2006 Aug; 20(13):1737-43. PubMed ID: 16931938
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
Regazzi M; Villani P; Gulminetti R; Cusato M; Brandolini M; Tinelli C; Barassi A; Maserati R; Sighinolfi L; D'Arminio Monforte A; Melzi D'Eril GV
Ther Drug Monit; 2011 Jun; 33(3):303-8. PubMed ID: 21544015
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae M; Clay PG; Anderson PL; Glaros AG
Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
20. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]